中国临床药理学杂志2024，Vol.40Issue(16)：2438-2441,4.DOI:10.13699/j.cnki.1001-6821.2024.16.029
PCSK9抑制药的药理作用机制研究现状及临床应用探讨
Research status of pharmacological mechanism of PCSK9 inhibitors and discussion of their clinical application
摘要
Abstract
Atherosclerosis caused by disorders of lipid metabolism is the main pathological basis of atherosclerotic cardiovascular disease.Statins are the cornerstone of lipid-modulating therapy for this type of disease,but in practice there are still some patients with suboptimal lipid management.Proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitors have been gradually applied as a new class of lipid-modulating drugs for the treatment in patients with this type of disease,and recent studies have shown that in addition to regulating lipid metabolism,PCSK9 inhibitors also have potential anti-inflammatory and anti-platelet activation effects.This article sorts out the multiple pharmacological mechanisms of action of PCSK9 inhibitors and the current status of clinical research of PCSK9 inhibitors.Besides,it discusses the factors that may affect the efficacy of PCSK9 inhibitors,in order to provide a reference for the safe and rational medication of PCSK9 inhibitors.关键词
前蛋白转化酶枯草溶菌素9抑制药/动脉粥样硬化性心血管疾病/作用机制/应用现状Key words
Proprotein convertase subtilisin/kexin type 9 inhibitors/atherosclerotic cardiovascular disease/mechanism of action/application status分类
医药卫生引用本文复制引用
莫文慧,徐思蕾,何霞,白妞妞,袁梦莹,李志敏,张娇,王菲,郑湲坤..PCSK9抑制药的药理作用机制研究现状及临床应用探讨[J].中国临床药理学杂志,2024,40(16):2438-2441,4.基金项目
四川省科技厅重点研发课题基金资助项目(2022YFS0272) （2022YFS0272）
个体化药物治疗四川省重点实验室开放课题基金资助项目(2021ZD02,2022YB02) （2021ZD02,2022YB02）
